Clearside Biomedical, Inc. to Report Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide at 2015 ARVO Meeting
Alpharetta, GA (April 29, 2015) - Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from their Phase 1/2 clinical trial will be presented at the 2015 Annual Meeting of the Association for Research and Vision in Ophthalmology (ARVO), May 3-7, 2015, in Denver, CO.
Debra Goldstein, MD, Professor of Ophthalmology and Director, Uveitis Service at the Northwestern University Feinberg School of Medicine will present the results of the six-month clinical trial:
- A Phase 1/2 Open-Label, Safety and Tolerability Study of Triamcinolone Acetonide Administered to the Suprachoroidal Space in Patients with Non-Infectious Uveitis. [Presentation #3557, May 5, 5:15p.m.-5:30p.m., 601/603, Retina/RPE Immunobiology]
One poster presentation will occur during the ARVO Annual Meeting:
- Noronha G, Blackwell K, Gilger BC, Kissner J, Patel SR, Walsh KT. Evaluation of Suprachoroidal CLS-TA and Oral Prednisone in a Porcine Model of Uveitis. [3110-D0306. May 5, 8:30a.m.-10:15 a.m., Exhibit Hall]
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside’s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema. Visit www.clearsidebio.com for more information.
Contacts
Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005
charlie.deignan@clearsidebio.com